Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HDMA Monitoring Efforts To Repeal Medicare "Non-Interference" Clause

This article was originally published in The Pink Sheet Daily

Executive Summary

The Healthcare Distribution Management Association is monitoring efforts to reopen the Medicare Modernization Act to remove the clause excluding government from price negotiations, Regulatory Affairs Director Falb noted at the group's distribution management conference. HDMA has also formed a task force to develop proposals for Medicaid reform.

You may also be interested in...

Medicaid Rx Purchasing Reform Could Be In Budget Reconciliation Bill

Reforming Medicaid prescription drug purchasing to reduce federal outlays is a "consensus item" among Senate Democrats and Republicans, Senate staffers say.

Medicare Rx "On Track And On Schedule," CMS' McClellan Says; "Non-Interference" Not An Issue

The Senate's rejection of legislation to allow HHS intervention in Medicare drug price negotiations reflects the Centers for Medicare & Medicaid Services' confidence that the new outpatient drug benefit will be working as planned on Jan. 1, CMS Administrator Mark McClellan said March 17

HHS Medicare Rx Price Negotiations Would Fail For Lack Of Force, CMS Says

The current Administration, as well as those in the future, would not be willing or able to enforce drug prices significantly below competitive market rates, CMS Chief Actuary Foster says in memo. Giving HHS price negotiating authority would lead to restrictions on drug choice, Administrator McClellan asserts.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts